1Gatzemeier U, von Pawel J, Gottfried M, Ten Velde GPM, Mattson K, et al. (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 3390-3399.
2Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3Odoux C, Albers A, Amoscato AA, Lotze MT, Wong MK (2002) TRAIL, Fasl and a blocking anti‐DR5 antibody augmentpaclitaxel‐induced apoptosis in human non‐small‐cell lung cancer. Int J Cancer 97: 458-465.
4Gold KA, Wistuba II, Kim ES (2012) New strategies in squamous cell carcinoma of the lung: identification of tumour drivers to personalize therapy. Clin Cancer Res 18: 3002-3007.
5Perez-Moreno P, Brambilla E, Thomas R, Soria JC. (2012) Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 18: 2443-2451.
6Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525.
7Sarto C, Binz PA, Mocarelli P (2000) Heat shock proteins in human cancer. Electrophoresis 21: 1218-1226.
8Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, et al. (2007) Hsp27 knockdown using nucleotide-based therapies inhibit tumour growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 6: 299-308.
9Shin KD, Lee MY, Shin DS, Lee S, Son KH, et al. (2005) Blocking tumour cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem280: 41439-41448.
10Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, et al. (1999) Hsp27 over expression inhibits doxorubicin–induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56: 185-194.
11Lee JH, Sun D, Cho KJ, Kim MS, Hong MH, et al. (2007) Over expression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay. J Cancer Res Clin Oncol 133: 37-46.
12Aldrian S, Trautinger F, Fröhlich I, Berger W, Micksche M, et al. (2002) Over expression of Hsp27 affects the metastatic phenotype of human melanoma cells in vitro. Cell Stress Chaperones 7: 177.
13Kanagasabai R, Krishnamurthy K, Druhan LJ, Ilangovan G (2011) Forced expression of Hsp27 reverses P-glycoprotein (ABCB1) mediated drug efflux and MDR1 gene expression in adriamycin resistant human breast cancer cells. J Biol Chem 286: 33289-33300.
14Socinski MA, Morris DE, Masters GA, Lilenbaum R (2003) Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123: 226S-243S.
15Black PM, Loeffler JS (2005) Cancer of the Nervous System. Lippincott Williams & Wilkins.
16Sharma A, Upadhyay AK, Bhat MK (2009) Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells. Cancer Biol Ther 8: 2106-2113.
17Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y (2001) Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer lett 168: 173-181.
18Hettingga JVE, Lemstra W, Meijer C, Los G, De Vries EGE, et al. (1996) Heat shock protein expression in cisplatin-sensitive and -resistant human tumor cells. Int J Cancer 67: 800-807.
19Zhang Y, Shen X (2007) Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin Cancer Res 13: 2855-2864.
20Piotrowicz RS, Weber LA, Hickey E, Levin EG. (1995) Accelerated growth and senescence of arterial endothelial cells expressing the small molecular weight heat-shock protein HSP27. FASEB J 9: 1079-1084.
21Mairesse N, Horman S, Mosselmans R, Galand P (1996) Antisense inhibition of the 27 kda heat shock protein production affects growth rate and cytoskeletal organization in mcf‐7 cells. Cell Biol Int 20: 205-212.
22Hayashi N, Peacock JW, Beraldi E, Zoubeidi A, Gleave ME, et al. (2011) Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ 19: 990-1002.
23Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, et al. (1993) The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53: 4443-4448.
24Hu Z, Lin D, Yuan J, Xiao T, Zhang H, et al. (2005) Over expression of osteopontin is associated with more aggressive phenotypes in human non–small cell lung cancer. Clin Cancer Res 11: 4646-4652.
25Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594.
26Lee JW, Kwak HJ, Lee JJ, Kim YN, Lee JW, et al. (2008) HSP27 regulates cell adhesion and invasion via modulation of focal adhesion kinase and MMP-2 expression. Eur J Cell Biol 87: 377-387.
27Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, et al. (2012) Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer 107: 63-70.
28Lavoie JN, Hickey E, Weber LA, Landry J (1993) Modulation of actin microfilament dynamics and fluid phase pinocytosis by phosphorylation of heat shock protein 27. J Biol Chem 268: 24210-24214.
29Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, et al. (2010) p38 Mitogen-Activated Protein Kinase–Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity. Cancer Res 70: 832-841.